Health & Environmental Research Online (HERO)


Print Feedback Export to File
7039145 
Journal Article 
A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance 
Perrio, MJ; Wilton, LV; Shakir, SA; , 
2007 
Drug Safety
ISSN: 0114-5916
EISSN: 1179-1942 
30 
681-695 
English 
Monitoring was required for the introduction of non-chlorofluorocarbon (CFC) propellants in metered dose inhalers (MDIs) to ensure that there were no unexpected adverse events due to the new products. A postmarketing surveillance study has been conducted to evaluate the introduction of the MDI Seretide Evohaler (hydrofluoroalkane-134a inhaler containing salmeterol and fluticasone propionate). 
Adult; Aerosol Propellants/adverse effects; Albuterol/adverse effects/analogs & derivatives; Androstadienes/adverse effects; Asthma/drug therapy; Bronchodilator Agents/adverse effects; Drug Combinations; England; Fluticasone-Salmeterol Drug Combination; Hydrocarbons, Fluorinated/adverse effects; Metered Dose Inhalers/adverse effects; Middle Aged; Pregnancy; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive/drug therapy